Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.45 |
| ▸ | MME | P08473 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526546 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL31174309 | 1.00 | ALDH1A1 (0.46) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL29352016 | 0.95 | ALDH1A1 (0.46) | ALDH1A1ENPEP | |
| SCHEMBL30272494 | 0.92 | ALDH1A1 (0.50) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL2933768 | 0.89 | ALDH1A1 (0.58) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL2933766 | 0.89 | ALDH1A1 (0.58) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL31025662 | 0.89 | ALDH1A1 (0.58) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL7441174 | 0.89 | ALDH1A1 (0.58) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL30818044 | 0.89 | ALDH1A1 (0.46) | ALDH1A1ENPEP | |
| SCHEMBL29641579 | 0.88 | ALDH1A1 (0.47) | ALDH1A1ENPEPMMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4650362-A1 | NEUROPROTECTIVE PSD-95 POLYPEPTIDE INHIBITOR AND USE THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2025-11-19 | — | — | EP | claimed |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | claimed |
| CN-120044159-A | Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application | 河北北方学院 | 2025-05-27 | — | — | CN | claimed |
| CN-119409797-A | Tide robust peptide synthesis method | 中肽生化有限公司 | 2025-02-11 | — | — | CN | claimed |
| WO-2024149230-A1 | NEUROPROTECTIVE PSD-95 POLYPEPTIDE INHIBITOR AND USE THEREOF | 北京拓界生物医药科技有限公司 | 2024-07-18 | — | — | WO | claimed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | claimed |
| CN-111393508-B | Preparation method of atosiban | 上海苏豪逸明制药有限公司 | 2023-05-12 | — | — | CN | claimed |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | claimed |
| US-20220289846-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-09-15 | — | — | US | claimed |
| EP-3997126-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-18 | — | — | EP | claimed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | claimed |
| CN-122011162-A | Chemical synthesis method of N-terminal domain of TIMP2 protein | 华南理工大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12516121-B2 | Antibodies to human programmed death receptor PD-1 | ZYDUS LIFESCIENCES LIMITED (IN) | 2026-01-06 | — | — | US | disclosed |
| EP-3481849-B1 | CHIMERIC DENGUE/ZIKA VIRUSES AS LIVE-ATTENUATED ZIKA VIRUS VACCINES | US HEALTH (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2020027689-A1 | NOVEL USES OF A COMBINATION OF JUNIPER BERRY EXTRACT AND CHARCOAL | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "СПЛАТ ГЛОБАЛ" | 2020-02-06 | — | — | WO | disclosed |
| US-20180314790-A1 | System, Method and Apparatus for Determining the Effect of Genetic Variants | METABOLON, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20170276669-A1 | PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-09-28 | — | — | US | disclosed |
| CN-106456633-A | Sugar metabolism improving agent | 三得利控股株式会社 | 2017-02-22 | — | — | CN | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | ALDH1A1 4851/4885ENPEP 1199/4885MME 1756/4885 |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | ALDH1A1 4851/4885ENPEP 1199/4885MME 1756/4885 |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | ALDH1A1 4851/4885ENPEP 1199/4885MME 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.